Ketogenic Diet for Osteoarthritis Pain and Mild Cognitive Impairment
This study is exploring whether a special eating plan called a well-formulated ketogenic diet can help reduce pain from osteoarthritis (OA) in your hip, knee, or shoulder, especially if you also have mild cognitive impairment (MCI). The ketogenic diet is a very low-carbohydrate, higher-fat diet that focuses on whole, nutrient-dense foods. Researchers believe that OA and MCI share similar underlying problems with inflammation and metabolism, and this diet might help by addressing these shared issues. The study will measure changes in your pain intensity, how pain affects your daily life, your overall health-related quality of life, and your physical function over 8 weeks. To join, you need to be between 55 and 75 years old, speak English, and have a diagnosis of both major joint osteoarthritis and mild cognitive impairment. You cannot participate if you have insulin-dependent diabetes, recent cancer treatment, a recent heart event, kidney stones, fibromyalgia, or are already on a ketogenic diet.
- Study design
- This is an interventional study with a planned enrollment of 10 participants. It is not specified if it is randomized or blinded.
- What's involved
- You would follow a supervised ketogenic diet for 8 weeks. Assessments will be conducted at the beginning and end of this 8-week period.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your pain intensity, quality of life, and physical function will be measured from enrollment to the end of treatment at 8 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Ketogenic Diet to Reduce Osteoarthritis Pain in MCI
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Pain intensity and pain interference using a Visual Analog ScaleFrom enrollment to the end of treatment at 8 weeks
Patient- and caregiver-reported outcome. 0-10 with higher scores reflecting worse pain.
- Health-related quality of life using a QuestionnaireFrom enrollment to end of treatment at 8 weeks
Patient- and caregiver-reported ouctome.The PROMIS-29+2 Profile is a patient-reported outcome measure with domain scores converted to standardized T-scores (mean = 50, SD = 10), where higher scores indicate worse symptoms for anxiety, depression, fatigue, sleep disturbance, and pain interference, better functioning for physical function, social participation, and cognitive function, and pain intensity is rated separately on a 0-10 scale with higher scores indicating greater pain.
- Physical Function via Functional Activities QuestionnaireFrom enrollment to end of treatment at 8 weeks.
Caregiver-reported outcome. FAQ is 0-30 with higher scores indicating worse impairment.
- Montreal Cognitive Assessment (MoCA) for brief global cognitive screeningFrom enrollment to end of treatment at 8 weeks.
Cognitive screener completed by the participant and administered by the study coordinator. The Montreal Cognitive Assessment (MoCA) is a 30-point cognitive screening tool assessing multiple cognitive domains, with total scores ranging from 0 to 30 and higher scores indicating better cognitive function.